New Genetic Recommendation on Cardiovascular Disease Released by
the EGAPP™ Working Group This month the independent Evaluation
of Genomic Applications in Practice and Prevention (EGAPP)
Working Group has released a new evidence-based recommendation
on the use of “cardiogenomic profiles” (or “heart health”),
which is a type of genetic test. These tests are being marketed
to physicians and the general public as a way to find out a
person’s risk of developing cardiovascular disease. Some of
these tests can be ordered online and without the involvement of
a physician. |What do cardiogenomic profiles This type of test
attempts to predict genetic risk for cardiovascular disease, and
looks for genetic variants that may be associated with an
increased risk of cardiovascular disease. The EGAPP Working
Group evaluated commercially-available cardiogenomic profiles
for analytic validity, clinical validity, and clinical utility.
They did not find enough evidence to indicate whether
cardiogenomic profiles should or should